Notice of Half Year Results and IONA Test Showcase

Premaitha Health PLC

("the Company")

Notification of Half Year Results and the IONA® Test Showcase

Manchester, UK - 25 November 2014 - Premaitha Health ('Premaitha') (AIM: NIPT), an innovative molecular diagnostics company developing the IONA® non-invasive prenatal test (NIPT), will be announcing its half year results for the six month period ended 30 September 2014 on Wednesday 10 December 2014.

On the day, there will be an extended analyst and investor meeting to present the results and showcase Premaitha's IONA® test - the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time. The IONA® test estimates the risk of the fetus having Trisomy 21 (Down's syndrome), Trisomy 18 (Edwards' syndrome) and Trisomy 13 (Patau's syndrome).

The meeting will commence at 11am at Instinctif Partners' offices at 65 Gresham Street, London EC2V 7NQ. Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email premiatha@instinctif.com to register.

-Ends-

About Premaitha Health

Premaitha Health (AIM: NIPT) is an innovative molecular diagnostics company employing the latest advances in DNA analysis technology to develop tests for non-invasive prenatal screening (NIPT) and other applications. Premaitha's flagship product, the IONA® test is the first non-invasive in vitro diagnostic product for prenatal screening, enabling clinical laboratories to offer CE-marked NIPT in-house for the first time.

The IONA® test estimates the risk of a fetus having Down's syndrome or other serious genetic diseases. The IONA® test has a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors' greater confidence in the result and reducing the need for unnecessary invasive follow-up tests and the associated anxiety and stress.

The IONA® test is a complete diagnostic system that is simple and standardised, enabling Premaitha's clinical laboratory customers to perform the test in their own facilities. This supports Premaitha's strategy to accelerate the broad dissemination of NIPT tests to benefit more laboratories, doctors and pregnant women.

Premaitha is listed on the London Stock Exchange's (AIM). Its R&D, manufacturing and commercial operation is located at Manchester Science Park, UK.

For further information please visit www.premaitha.com or email iona@premaitha.com.